Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra (fo ...
known as the Malvinas Islands, at a war memorial in Buenos Aires, Argentina, Wednesday, April 2, 2025. (AP Photo/Natacha Pisarenko) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback